Models of cancer
Models of cancer come in a variety of forms, from cancer cell lines in culture to genetically modified mice. In between are a host of organisms that also contribute to our understanding of this disease. Yeast, for example, have added much to our knowledge of the cell cycle and the maintenance of cell polarity, whereas egg extracts from Xenopus laevis have helped our comprehension of biochemical pathways and protein modifications essential for normal cellular function. Work on Caenorhabditis elegans was crucial for our grasp of the genetic pathway that regulates programmed cell death, and research in Drosophila melanogaster has identified several pathways that are deregulated during cancer formation, including the Hippo tumour suppressor pathway. Whether results are generated by cell lines, yeast, mouse orthotopic tumour models or zebrafish the cumulative information from these models should help us to understand in greater detail the subtleties of cancer formation.
2013
September 2013 Vol 13 No 9
Zebrafish cancer: the state of the art and the path forward
Richard White, Kristin Rose & Leonard Zon
doi:10.1038/nrc3589
March 2013 Vol 13 No 3
Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics
Cayetano Gonzalez
doi:10.1038/nrc3461
2011
January 2011 Vol 11 No 1
Cell lineage and cell death: Caenorhabditis elegans and cancer research
Malia B. Potts & Scott Cameron
doi:10.1038/nrc2984
2010
October 2010 Vol 10 No 10
Harnessing transposons for cancer gene discovery
Neal G. Copeland & Nancy A. Jenkins
doi:10.1038/nrc2916
July 2010 Vol 10 No 7
Non-germline genetically engineered mouse models for translational cancer research
Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe & Lynda Chin
doi:10.1038/nrc2877
June 2010 Vol 10 No 6
Cell line misidentification: the beginning of the end
American Type Culture Collection Standards Development Organization Workgroup ASN-0002
doi:10.1038/nrc2852
April 2010 Vol 10 No 4
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sreenath V. Sharma, Daniel A. Haber & Jeff Settleman
doi:10.1038/nrc2820